Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05336201 · ClinicalTrials.gov registry record · Phase 2
Cognitive Remediation Intervention to Prepare for Transition of Care
A Phase 2 study of Sickle Cell Disease and Cognitive Impairment, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05336201 is a Phase 2 study of Sickle Cell Disease and Cognitive Impairment that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 120 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05336201, a Phase 2 study of Sickle Cell Disease and Cognitive Impairment, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Randomized Controlled Trial (RTC) testing the efficacy of a telehealth adaptation of the Cognitive-Remediation of Executive and Adaptive Deficits in Youth (C-READY) intervention to prepare adolescents with sickle cell disease for transition of care.
Conditions Studied
Interventions
- BEHAVIORAL CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05336201
The ClinicalTrials.gov registry entry for NCT05336201 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (59% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) is the first listed.
NCT05336201 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT05336201 about?
NCT05336201 is a clinical study titled "Cognitive Remediation Intervention to Prepare for Transition of Care". Randomized Controlled Trial (RTC) testing the efficacy of a telehealth adaptation of the Cognitive-Remediation of Executive and Adaptive Deficits in Youth (C-READY) intervention to prepare adolescents with sickle cell disease for transition of care.
What is the current status of trial NCT05336201?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2022-07-01. Estimated completion is 2027-06-30.
What conditions does trial NCT05336201 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Cognitive Impairment, Adolescent Behavior, Self Efficacy, Coping Skills.
What interventions are being tested in trial NCT05336201?
The interventions under investigation include: CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05336201?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05336201 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.